Hyperlipoproteinemia type II
Drug research and approvals for hyperlipoproteinemia type II: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 50 studies of hyperlipoproteinemia type II are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 50
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2)NCT07948226 · Not applicable · Institut Pasteur de Lille · starts Nov 4, 2026
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNCT07839936 · Phase 2 · Eli Lilly and Company · starts Sep 24, 2026
- A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaNCT07695597 · Phase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts Jul 15, 2026
- Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat…NCT07614958 · Phase 3 · A. Menarini International Licensing S.A. · starts May 6, 2026
- Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous…NCT07591298 · Phase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts May 24, 2026
- A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabNCT07543731 · Not reported · Novartis Pharmaceuticals · starts Apr 2, 2026
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasNCT07491172 · Phase 1 · CRISPR Therapeutics AG · starts Jun 21, 2024
- A Dose-exploration Study of EDP167 in HoFHNCT07489209 · Phase 2 · Eddingpharm (Zhuhai) Co., Ltd. · starts Feb 6, 2026
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaNCT07473843 · Phase 3 · Arrowhead Pharmaceuticals · starts Oct 1, 2026
Approved 16
- AtorvastatinHMG-CoA reductase inhibitor
- EvolocumabSubtilisin/kexin type 9 inhibitor
- AlirocumabSubtilisin/kexin type 9 inhibitor
- EvinacumabAngiopoietin-related protein 3 inhibitor
- LomitapideMicrosomal triglyceride transfer protein inhibitor
- EzetimibeNiemann-Pick C1-like protein 1 inhibitor
- MipomersenApo-B 100 mRNA antisense inhibitor
- RosuvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- ColesevelamBile acids sequestering agent
- PitavastatinHMG-CoA reductase inhibitor
- FluvastatinHMG-CoA reductase inhibitor
- PravastatinHMG-CoA reductase inhibitor
- AmlodipineVoltage-gated L-type calcium channel blocker
- Bempedoic acidATP-citrate synthase inhibitor
- Inclisiran sodiumPCSK9 mRNA rnai inhibitor
Phase 3 11
- AnacetrapibCholesteryl ester transfer protein inhibitor
- TorcetrapibCholesteryl ester transfer protein inhibitor
- LaropiprantProstanoid DP receptor antagonist
- Niacin
- CholestyramineBile acids sequestering agent
- Omega-3-ACID ethyl esters
- EprotiromeThyroid hormone receptor beta-1 agonist
- BococizumabSubtilisin/kexin type 9 inhibitor
- TafolecimabSubtilisin/kexin type 9 inhibitor
- OngericimabSubtilisin/kexin type 9 inhibitor
- LerodalcibepSubtilisin/kexin type 9 inhibitor
Phase 2 5
- ImplitapideMicrosomal triglyceride transfer protein inhibitor
- ResmetiromThyroid hormone receptor beta-1 agonist
- SeladelparPeroxisome proliferator-activated receptor delta agonist
- 2-(aminomethyl)PHENOL
- Enlicitide
How its trials ended
241 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 75 whose ending is known, 69% met their primary endpoint, 5% missed it and 25% stopped early.
- Completed, result not reported7732%
- Ongoing6427%
- Met its primary endpoint5222%
- Status unknown2510%
- Stopped: other or unclear146%
- Missed its primary endpoint42%
- Stopped: lack of efficacy31%
- Stopped: enrollment or feasibility1<1%
- Stopped: sponsor or business decision1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA